SEC Company Response from INNOCAN PHARMA (INNPF) — Sep 22, 2025

INNOCAN PHARMA Corp
Date: Sept. 22, 2025 · CIK: 0001889791 · Accession: 0001493152-25-014449

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-288899

Date

Sept. 22, 2025

Author

PHARMA CORPORATION

Form

CORRESP

Company

INNOCAN PHARMA Corp

Letter

Innocan Pharma Corporation

1015, 926 – 5 Avenue SW

Calgary, Alberta T2P 0N7, Canada

September 22, 2025

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

RE: Innocan Pharma Corporation (CIK 0001889791)

Registration Statement No. 333-288899 on Form F-1 (the “Registration Statement”)

Ladies and Gentlemen:

Innocan Pharma Corporation (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on September 24, 2025 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling David Huberman at 312.364.1633. The Company hereby authorizes Mr. Huberman to orally modify or withdraw this request for acceleration.

Very
truly yours,
INNOCAN
PHARMA CORPORATION

Show Raw Text

CORRESP
1
filename1.htm

Innocan
Pharma Corporation

1015,
926 – 5 Avenue SW

Calgary,
Alberta T2P 0N7, Canada

September
22, 2025

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    RE:
    Innocan
    Pharma Corporation (CIK 0001889791)

    Registration
    Statement No. 333-288899 on Form F-1 (the “Registration Statement”)

Ladies
and Gentlemen:

Innocan
Pharma Corporation (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may
become effective on September 24, 2025 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling David Huberman at 312.364.1633. The Company hereby authorizes Mr. Huberman to orally modify or withdraw
this request for acceleration.

    Very
    truly yours,

    INNOCAN
    PHARMA CORPORATION

    By:
    /s/
    Iris Bincovich

    Iris
    Bincovich

    Chief Executive Officer

SecProbe.io